Editas Medicine Inc (NAS:EDIT)
$ 5.2075 0.03 (0.58%) Market Cap: 428.25 Mil Enterprise Value: 166.22 Mil PE Ratio: 0 PB Ratio: 1.45 GF Score: 52/100

Q2 2019 Editas Medicine Inc Earnings Call Transcript

Aug 06, 2019 / 09:00PM GMT
Release Date Price: $24.63 (+2.93%)
Operator

Good afternoon, and welcome to Editas Medicine Second Quarter 2019 Conference Call. (Operator Instructions) Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Mark Mullikin, Vice President of Finance and Investor Relations at Editas Medicine. Please go ahead.

Mark J. Mullikin
Editas Medicine, Inc. - Senior Director of Finance & IR

Thank you, operator. Good afternoon, everyone, and welcome to our second quarter 2019 conference call. Shortly after the market closed, we issued a press release providing our financial results and corporate updates for the second quarter of 2019. A replay of today's call will be available on the Investors and Media section of our website approximately 2 hours after its completion. After our prepared remarks, we will open the call for Q&A.

As a reminder, various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot